Then, anti-CTLA-4, anti-PD-1 and anti-PD-L1 monoclonal antibodies and other immune checkpoint inhibitors have been markedly successful in treating diverse cancer patients with melanoma, non–small-cell lung cancer, and ovarian cancer [10–12]. This evidence concerns the gene CD274 and cancer.